GlassScriptPhysician profile
Sylvie Lemire
NPI 1659793917
$1,902.05
in general payments reported to CMS, 2019-2025
30 companies · $420 in 2025
The $420 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $102 · 2022: $85.76 · 2023: $538 · 2024: $757 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,714.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $243.67 | 2022-2025 | |
| Lilly USA, LLC | $193.24 | 2023 | Mounjaro, Emgality, Jardiance |
| Novartis Pharmaceuticals Corporation | $122.07 | 2021-2025 | |
| Ucb, INC. | $112.74 | 2024-2025 | Rystiggo, Briviact |
| Neurocrine Biosciences, INC. | $101.81 | 2024-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $98.77 | 2024 | Ponvory |
| Abbvie INC. | $97.60 | 2022-2024 | |
| Lundbeck LLC | $89.59 | 2024-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $88.75 | 2024-2025 | Austedo Xr, Austedo Xr |
| Glaxosmithkline, LLC. | $66.31 | 2022-2023 | Shingrix, Arexvy |
| Amgen INC. | $58.78 | 2021-2023 | Repatha, Otezla |
| Acadia Pharmaceuticals INC | $58.20 | 2024-2025 | Nuplazid |
| Bausch Health US, LLC | $57.37 | 2023 | Aplenzin |
| Eisai INC. | $53.85 | 2024 | |
| Genentech USA, INC. | $48.69 | 2025 | Ocrevus Zunovo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $47.55 | 2023 | Rybelsus, Ozempic, Wegovy |
| Esperion Therapeutics, INC. | $42.98 | 2023 | Nexletol |
| Xeris Pharmaceuticals, INC. | $37.32 | 2021 | |
| Phadia US INC. | $37.02 | 2023 | Immunocap |
| Astrazeneca Pharmaceuticals LP | $33.53 | 2023 | Farxiga |
| Alexion Pharmaceuticals, INC. | $27.39 | 2025 | Ultomiris |
| Janssen Pharmaceuticals, INC | $26.71 | 2021 | |
| Argenx US, INC. | $25.28 | 2025 | Vyvgart Hytrulo |
| Sumitomo Pharma America, INC. | $24.25 | 2024 | Aptiom |
| Bayer Healthcare Pharmaceuticals INC. | $21.02 | 2023 | |
| Csl Behring | $19.59 | 2024 | Hizentra |
| Catalyst Pharmaceuticals, INC. | $19.24 | 2024 | |
| Idorsia Pharmaceuticals US INC | $18.72 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $16.41 | 2023 | Belsomra |
| Amneal Pharmaceuticals LLC | $13.60 | 2025 | Crexont |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sylvie Lemire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.